Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph not_applicable
2
33%
Ph phase_2
1
17%
Ph phase_3
1
17%
Ph phase_4
2
33%

Phase Distribution

0

Early Stage

1

Mid Stage

3

Late Stage

Phase Distribution6 total trials
Phase 2Efficacy & side effects
1(16.7%)
Phase 3Large-scale testing
1(16.7%)
Phase 4Post-market surveillance
2(33.3%)
N/ANon-phased studies
2(33.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Active(3)
Completed(2)
Other(1)

Detailed Status

Not yet recruiting3
Completed2
unknown1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 21 (16.7%)
Phase 31 (16.7%)
Phase 42 (33.3%)
N/A2 (33.3%)

Trials by Status

unknown117%
completed233%
not_yet_recruiting350%

Recent Activity

0 active trials
Showing 5 of 6
not_yet_recruitingphase_4

Dapagliflozin in Active Lupus Nephritis

NCT07323524
completedphase_3

SGLT2 Inhibitors in Non-Diabetic CKD: Effects on Vascular Calcification and Anemia

NCT07344922
completednot_applicable

Comparative Effects of Aspirin and SGLT2 Inhibitors on Liver Enzymes, Lipid Profile, and FibroScan Findings in Non-Alcoholic Fatty Liver Disease

NCT07338331
not_yet_recruitingnot_applicable

Epicardial Adipose Tissue-Targeted DApagliflozin for Reducing Electrical Remodeling in Atrial Fibrillation

NCT07331727
not_yet_recruitingphase_4

A Comparison of Effectiveness, Safety, and Cost-effectiveness of Dapagliflozin and Empagliflozin in Patients With Type 2 Diabetes Mellitus and High Body Mass Index (BMI)

NCT07311551
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT07323524Phase 4

Dapagliflozin in Active Lupus Nephritis

Not Yet Recruiting
NCT07344922Phase 3

SGLT2 Inhibitors in Non-Diabetic CKD: Effects on Vascular Calcification and Anemia

Completed
NCT07338331Not Applicable

Comparative Effects of Aspirin and SGLT2 Inhibitors on Liver Enzymes, Lipid Profile, and FibroScan Findings in Non-Alcoholic Fatty Liver Disease

Completed
NCT07331727Not Applicable

Epicardial Adipose Tissue-Targeted DApagliflozin for Reducing Electrical Remodeling in Atrial Fibrillation

Not Yet Recruiting
NCT07311551Phase 4

A Comparison of Effectiveness, Safety, and Cost-effectiveness of Dapagliflozin and Empagliflozin in Patients With Type 2 Diabetes Mellitus and High Body Mass Index (BMI)

Not Yet Recruiting
NCT05014594Phase 2

Sodium-glucose Linked Transporter 2 (SGLT-2) Inhibitors in Recurrent Ascites: a Pilot RCT

Unknown

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6